NCT07205926View on ClinicalTrials.gov

First in Human Dose Escalation Study Evaluating the Safety and Immunogenicity of IVT's Shigella-04 Vaccine in Healthy Young Adults

PHASE1RecruitingINTERVENTIONAL
Enrollment

60

Participants

Timeline

Start Date

October 9, 2025

Primary Completion Date

January 26, 2026

Study Completion Date

August 21, 2026

Conditions
ShigellaDiarrhea
Interventions
BIOLOGICAL

IVT Shigella-04

Preventative vaccine for Shigella protection against 4 unique serotypes

BIOLOGICAL

Placebo (0.9% saline)

Subjects dosed with 0.9% saline

Trial Locations (1)

45227

RECRUITING

Medpace Clinical Pharmacology Unit, Cincinnati

Sponsors

Lead Sponsor

Inventprise Inc.
All Listed Sponsors
lead

Inventprise Inc.

INDUSTRY

NCT07205926 - First in Human Dose Escalation Study Evaluating the Safety and Immunogenicity of IVT's Shigella-04 Vaccine in Healthy Young Adults | Biotech Hunter | Biotech Hunter